SOLD OUT – The BioMelbourne Network with Phillips Ormonde Fitzpatrick present

Health-Tech and Hype: Lessons from Theranos

The rise and fall of Theranos has seen the unraveling of this US based health-technology start-up, with the once heralded company now under criminal investigation and facing a class action. Join our panel of an experts for a discussion on the lessons from Theranos and the future implications for IVDs, personalised medicine and “disruptive” healthcare technology. Beyond the hype, what will the legacy of Theranos be on the regulatory, governance and investor landscape for healthcare start-ups and the broader industry?

Panellists:

• Dr Alastair Hodges, Chief Scientific Officer, Universal BioSensors
• Lusia Guthrie, CEO, LBT Innovations
• David Lester, CEO of NIESM Pty Ltd and Former VP Human Health Solutions, Theranos
• Pierre Nathie, Business Development Manager, Universal BioSensors

Date: Tuesday 5^th July, 2016

Time: Registration from 3:45pm for 4:00pm – 5:30pm followed by a networking session

Address: Phillips Ormonde Fitzpatrick, Level 16/333 Collins St, Melbourne VIC 3000

Price:
Members – $65
Non-Members – $130
(Prices include GST)

To check if your organisation is a member click here

 

About the speakers:

Dr Alastair HodgesBSc. (Hons.), Ph.D., Chief Scientist, Universal BioSensors

Alastair has been working in the field of electrochemical sensors for the last 18 years and has served as our Chief Scientist since April 2002.  Alastair has a BSc. (Hons.) in chemistry and gained a Ph.D. in electrochemistry from the University of Melbourne in 1987.  Alastair worked as a research scientist, then senior and principle research scientist in the Defense Science and Technology Organization and the CSIRO in the fields of electrochemistry and transport processes, particularly involving membranes, until 1995, when he joined Memtec Limited to work on sensor technologies. Memtec was involved in the operation, design and installation of filtration and separation products for water supply and waste water recycling plants. From 1999 to 2001 Alastair led a team that worked in the US on the development of glucose sensor technology.

Lusia Guthrie, CEO, LBT Innovations

Lusia Guthrie has over 30 years’ experience in the pathology laboratory and pharmaceutical industries. After launching her career as a medical laboratory scientist, she spent 13 years in various managerial roles at the pharmaceutical company, FH Faulding & Co, before co-founding LBT Innovations in 2004. She has broad executive and management experience, with specific expertise in product development, production and supply chain management, industrial relations, regulatory compliance, and intellectual property management.

Lusia has previously served on the Manufacturing Consultative Council for the Government of South Australia, the Commonwealth Government’s Future Manufacturing Industry Innovation Council, and the Assessment Panel for the Medical Device Commercialisation Program at the SA Department of Trade and Economic Development.

Dr David Lester, CEO of NIESM Pty Ltd and Former VP Human Health Solutions, Theranos

Dr Lester is a very experienced leader in development of medical technologies for clinical practice and clinical trials. He has had established medtech innovation divisions of major pharmaceutical companies (Pfizer and Pharmacia) supporting development and commercialization of numerous billion dollar pharmaceuticals. David had a senior management position at the Center for Drug Evaluation and Research at the US FDA. He has held executive positions dealing with all phases of development and commercialisation of several medtech diagnostic companies. He is a co-founder of the health and wellness diagnostic company, Inside Tracker, and a co-inventor of their patent. He is a recognized leader in the development of innovative approaches to lowering costs and improving healthcare outcomes through integration of medical technologies into advanced solutions.

Pierre Nathie, Business Development Manager, Universal BioSensors

My 25-year career is focused on bringing medtech and biotech innovations to the market.

Starting in R&D after a MSc in Biotechnology, I have rapidly moved into sales; then after an MBA, into marketing and general management positions across Europe, for British and US companies, before relocating in Australia.
Along this journey I have learned a few things, including:

• The commercial execution part of a project is often largely underestimated in terms of time, costs and risks.
• Marketing catalyses scientific work; it doesn’t replace it.
• Doing what is right is the only sustainable way forward.